Pfizer (PFE) Cash from Financing Activities (2009 - 2026)

Pfizer has disclosed Cash from Financing Activities across 18 years of filings, most recently posting -$2.9 billion for Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 45.36% year-over-year to -$2.9 billion; the TTM figure through Mar 2026 stood at -$7.9 billion (up 67.81% YoY), while the FY2025 annual figure was -$10.3 billion, up 39.88% from the prior year.
• Cash from Financing Activities eased to -$2.9 billion in Q1 2026, from $596.0 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for PFE reached as high as $27.2 billion in Q3 2023 and fell as low as -$12.0 billion in Q3 2024.
• The 5-year median for Cash from Financing Activities is -$2.9 billion (2026), against an average of -$1.4 billion.
• Annual changes were most pronounced in 2023 — Cash from Financing Activities soared 978.33% — and 2024, when it tumbled 218.23%.
• A 5-year view of Cash from Financing Activities shows it stood at -$9.8 billion in 2022, then jumped by 155.42% to $5.4 billion in 2023, then tumbled by 320.98% to -$12.0 billion in 2024, then soared by 104.96% to $596.0 million in 2025, then slumped by 579.19% to -$2.9 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered -$2.9 billion, $596.0 million, and -$2.5 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.